Skip to main
LGVN
LGVN logo

Longeveron (LGVN) Stock Forecast & Price Target

Longeveron (LGVN) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Longeveron Inc. is at the forefront of developing innovative regenerative medicines, specifically Lomecel-B, which has demonstrated significant safety and efficacy in clinical trials, particularly in treating Hypoplastic Left Heart Syndrome (HLHS) with a remarkable 100% five-year transplant-free survival rate in a Phase 1b study. The ongoing Phase 2b study holds the potential for FDA approval, given that no competing drugs have reached this level of clinical evidence, enhancing the prospect for future revenue generation. Furthermore, a discounted cash flow analysis suggests a substantial upside, indicating substantial growth potential compared to the current share price, supported by the strength of the company's pipeline and successful trial outcomes.

Bears say

Longeveron Inc. has experienced a significant stock depreciation of approximately 56% year-to-date, primarily attributed to concerns regarding unexpected safety signals during the clinical development of its investigational product, Lomecel-B, particularly in patients with Hypoplastic Left Heart Syndrome (HLHS). Additionally, the company faces risks related to the efficacy outcomes of the ongoing ELPIS II study and potential delays in securing necessary funding for further clinical development and U.S. commercialization. Further compounding these challenges are regulatory hurdles, market penetration issues, and potential dilution risks, which collectively contribute to a negative outlook for the stock.

Longeveron (LGVN) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Longeveron and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Longeveron (LGVN) Forecast

Analysts have given Longeveron (LGVN) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Longeveron (LGVN) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Longeveron (LGVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.